Concepts (258)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Physical Therapy Specialty | 5 | 2016 | 39 | 1.090 |
Why?
|
| Clinical Competence | 6 | 2022 | 657 | 0.930 |
Why?
|
| Attitude of Health Personnel | 4 | 2016 | 442 | 0.810 |
Why?
|
| Neonatal Abstinence Syndrome | 1 | 2021 | 27 | 0.740 |
Why?
|
| Lysosomal Storage Diseases | 2 | 2016 | 6 | 0.710 |
Why?
|
| Rare Diseases | 2 | 2016 | 41 | 0.700 |
Why?
|
| Health Personnel | 2 | 2022 | 286 | 0.680 |
Why?
|
| Physical Therapy Modalities | 3 | 2013 | 133 | 0.680 |
Why?
|
| Video Games | 3 | 2017 | 39 | 0.660 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2016 | 114 | 0.640 |
Why?
|
| Physicians | 1 | 2022 | 324 | 0.610 |
Why?
|
| Gram-Negative Bacteria | 5 | 2021 | 55 | 0.610 |
Why?
|
| Anti-Bacterial Agents | 7 | 2021 | 1026 | 0.580 |
Why?
|
| Physical Therapists | 2 | 2017 | 21 | 0.570 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2016 | 24 | 0.570 |
Why?
|
| Canada | 6 | 2022 | 267 | 0.550 |
Why?
|
| Acinetobacter baumannii | 4 | 2019 | 22 | 0.510 |
Why?
|
| Antitubercular Agents | 4 | 2016 | 57 | 0.490 |
Why?
|
| Siderophores | 4 | 2021 | 16 | 0.460 |
Why?
|
| Patient Advocacy | 1 | 2013 | 40 | 0.430 |
Why?
|
| Brain Injuries | 2 | 2013 | 268 | 0.420 |
Why?
|
| Research Design | 1 | 2016 | 729 | 0.410 |
Why?
|
| Psychometrics | 2 | 2016 | 514 | 0.410 |
Why?
|
| Nitroso Compounds | 3 | 2011 | 16 | 0.410 |
Why?
|
| Healthcare Disparities | 2 | 2013 | 378 | 0.410 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 4 | 2019 | 47 | 0.400 |
Why?
|
| Radiography, Interventional | 2 | 2016 | 49 | 0.390 |
Why?
|
| Continuity of Patient Care | 1 | 2013 | 170 | 0.390 |
Why?
|
| Educational Measurement | 2 | 2011 | 254 | 0.390 |
Why?
|
| Tuberculosis | 3 | 2016 | 77 | 0.370 |
Why?
|
| Mycobacterium tuberculosis | 3 | 2016 | 103 | 0.370 |
Why?
|
| Ferrous Compounds | 3 | 2019 | 18 | 0.360 |
Why?
|
| Peer Review | 1 | 2010 | 16 | 0.360 |
Why?
|
| Professional Competence | 1 | 2011 | 100 | 0.350 |
Why?
|
| Monobactams | 2 | 2021 | 2 | 0.350 |
Why?
|
| Licensure | 1 | 2010 | 18 | 0.350 |
Why?
|
| Interviews as Topic | 6 | 2016 | 392 | 0.350 |
Why?
|
| Ontario | 5 | 2020 | 24 | 0.350 |
Why?
|
| Program Evaluation | 3 | 2017 | 502 | 0.350 |
Why?
|
| Writing | 1 | 2010 | 29 | 0.340 |
Why?
|
| Stroke Rehabilitation | 4 | 2016 | 335 | 0.340 |
Why?
|
| Microbial Sensitivity Tests | 9 | 2021 | 226 | 0.330 |
Why?
|
| Patient Discharge | 1 | 2011 | 294 | 0.330 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 177 | 0.330 |
Why?
|
| Stroke | 4 | 2011 | 2163 | 0.310 |
Why?
|
| Humans | 36 | 2022 | 68618 | 0.310 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2016 | 767 | 0.310 |
Why?
|
| Daptomycin | 2 | 2018 | 11 | 0.300 |
Why?
|
| Videoconferencing | 1 | 2008 | 43 | 0.300 |
Why?
|
| Molecular Structure | 10 | 2019 | 397 | 0.300 |
Why?
|
| Imines | 1 | 2007 | 6 | 0.300 |
Why?
|
| Consumer Behavior | 1 | 2008 | 68 | 0.300 |
Why?
|
| Education | 1 | 2008 | 83 | 0.290 |
Why?
|
| beta-Lactams | 2 | 2017 | 29 | 0.290 |
Why?
|
| Peptides | 3 | 2019 | 455 | 0.290 |
Why?
|
| Drug Discovery | 2 | 2018 | 94 | 0.270 |
Why?
|
| Biological Products | 1 | 2007 | 78 | 0.270 |
Why?
|
| Catechols | 4 | 2019 | 14 | 0.260 |
Why?
|
| Qualitative Research | 4 | 2020 | 369 | 0.260 |
Why?
|
| Imidazoles | 2 | 2016 | 175 | 0.250 |
Why?
|
| Catheterization, Central Venous | 1 | 2006 | 89 | 0.250 |
Why?
|
| Thiazines | 2 | 2016 | 4 | 0.250 |
Why?
|
| Review Literature as Topic | 1 | 2003 | 24 | 0.220 |
Why?
|
| Hospital Restructuring | 1 | 2002 | 3 | 0.210 |
Why?
|
| Contrast Media | 1 | 2006 | 595 | 0.210 |
Why?
|
| Evidence-Based Medicine | 2 | 2016 | 438 | 0.200 |
Why?
|
| Professional Practice | 1 | 2002 | 47 | 0.200 |
Why?
|
| Hospitals, Teaching | 1 | 2002 | 65 | 0.200 |
Why?
|
| Aztreonam | 1 | 2021 | 6 | 0.200 |
Why?
|
| Neoplasms | 1 | 2013 | 1667 | 0.200 |
Why?
|
| Research | 1 | 2003 | 214 | 0.200 |
Why?
|
| Gram-Positive Bacteria | 2 | 2018 | 23 | 0.200 |
Why?
|
| Morphine | 1 | 2021 | 76 | 0.180 |
Why?
|
| Oxazoles | 2 | 2011 | 17 | 0.180 |
Why?
|
| Teicoplanin | 1 | 2019 | 5 | 0.180 |
Why?
|
| Female | 16 | 2021 | 38074 | 0.170 |
Why?
|
| Professional Role | 1 | 2020 | 80 | 0.170 |
Why?
|
| Physician Assistants | 1 | 2020 | 47 | 0.170 |
Why?
|
| Structure-Activity Relationship | 6 | 2017 | 420 | 0.170 |
Why?
|
| Sleep | 1 | 2021 | 263 | 0.160 |
Why?
|
| Hydroxamic Acids | 2 | 2016 | 84 | 0.160 |
Why?
|
| Nurse Practitioners | 2 | 2016 | 90 | 0.160 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 2077 | 0.160 |
Why?
|
| Regression Analysis | 2 | 2010 | 737 | 0.150 |
Why?
|
| Occupational Therapists | 1 | 2017 | 5 | 0.150 |
Why?
|
| Isocyanates | 1 | 2016 | 1 | 0.140 |
Why?
|
| Virtual Reality Exposure Therapy | 1 | 2016 | 7 | 0.140 |
Why?
|
| Penicillins | 1 | 2016 | 32 | 0.140 |
Why?
|
| Cephalosporins | 1 | 2016 | 59 | 0.140 |
Why?
|
| Neurofibrillary Tangles | 1 | 2016 | 8 | 0.140 |
Why?
|
| Isoquinolines | 1 | 2016 | 37 | 0.140 |
Why?
|
| Research Personnel | 1 | 2016 | 83 | 0.130 |
Why?
|
| Molecular Imaging | 1 | 2016 | 45 | 0.130 |
Why?
|
| Cryosurgery | 1 | 2016 | 53 | 0.130 |
Why?
|
| Vascular Malformations | 1 | 2016 | 19 | 0.130 |
Why?
|
| Analgesics, Opioid | 1 | 2021 | 498 | 0.130 |
Why?
|
| Thiazoles | 1 | 2016 | 95 | 0.130 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 445 | 0.130 |
Why?
|
| Workload | 1 | 2016 | 103 | 0.130 |
Why?
|
| Hydrocarbons, Aromatic | 1 | 2015 | 13 | 0.130 |
Why?
|
| Drug Design | 1 | 2016 | 107 | 0.130 |
Why?
|
| Positron-Emission Tomography | 1 | 2016 | 160 | 0.130 |
Why?
|
| Ultrasonography, Interventional | 1 | 2016 | 119 | 0.130 |
Why?
|
| Infant, Newborn | 1 | 2021 | 2455 | 0.120 |
Why?
|
| User-Computer Interface | 1 | 2016 | 230 | 0.120 |
Why?
|
| Drug Delivery Systems | 1 | 2016 | 236 | 0.120 |
Why?
|
| Internship and Residency | 2 | 2014 | 596 | 0.120 |
Why?
|
| Piperazines | 1 | 2016 | 206 | 0.120 |
Why?
|
| Infant | 1 | 2021 | 2891 | 0.120 |
Why?
|
| Oncology Nursing | 1 | 2014 | 24 | 0.120 |
Why?
|
| Pyridines | 1 | 2016 | 261 | 0.120 |
Why?
|
| Medical Oncology | 1 | 2014 | 110 | 0.110 |
Why?
|
| Iron | 2 | 2012 | 197 | 0.110 |
Why?
|
| Spiro Compounds | 1 | 2013 | 14 | 0.110 |
Why?
|
| Education, Professional | 1 | 2013 | 25 | 0.110 |
Why?
|
| Child Behavior | 1 | 2013 | 56 | 0.110 |
Why?
|
| Sulfhydryl Compounds | 1 | 2013 | 73 | 0.110 |
Why?
|
| Inservice Training | 1 | 2013 | 68 | 0.110 |
Why?
|
| Amoxicillin | 1 | 2012 | 10 | 0.100 |
Why?
|
| Ampicillin | 1 | 2012 | 17 | 0.100 |
Why?
|
| Antineoplastic Agents | 2 | 2011 | 1070 | 0.100 |
Why?
|
| Retrospective Studies | 3 | 2021 | 7277 | 0.100 |
Why?
|
| Pimenta | 1 | 2011 | 1 | 0.100 |
Why?
|
| Syzygium | 1 | 2011 | 1 | 0.100 |
Why?
|
| Piper nigrum | 1 | 2011 | 1 | 0.100 |
Why?
|
| Motivation | 2 | 2013 | 561 | 0.100 |
Why?
|
| Sesquiterpenes | 1 | 2011 | 41 | 0.100 |
Why?
|
| Male | 11 | 2017 | 37321 | 0.100 |
Why?
|
| Motor Skills | 1 | 2011 | 88 | 0.090 |
Why?
|
| Family | 1 | 2013 | 293 | 0.090 |
Why?
|
| Longitudinal Studies | 2 | 2011 | 1054 | 0.090 |
Why?
|
| Chelating Agents | 1 | 2011 | 47 | 0.090 |
Why?
|
| Surveys and Questionnaires | 3 | 2017 | 2800 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2014 | 310 | 0.090 |
Why?
|
| Plant Extracts | 1 | 2011 | 122 | 0.090 |
Why?
|
| Documentation | 1 | 2011 | 83 | 0.090 |
Why?
|
| Tubulin Modulators | 1 | 2010 | 10 | 0.090 |
Why?
|
| Adolescent Behavior | 1 | 2013 | 264 | 0.090 |
Why?
|
| Acrylamides | 1 | 2010 | 12 | 0.090 |
Why?
|
| Attitude | 1 | 2011 | 121 | 0.090 |
Why?
|
| Oligopeptides | 1 | 2011 | 152 | 0.090 |
Why?
|
| Patient Compliance | 1 | 2013 | 402 | 0.090 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2011 | 346 | 0.090 |
Why?
|
| Patient Participation | 1 | 2011 | 146 | 0.090 |
Why?
|
| Triazoles | 1 | 2010 | 43 | 0.090 |
Why?
|
| Databases as Topic | 1 | 2010 | 49 | 0.090 |
Why?
|
| Ergosterol | 1 | 2009 | 3 | 0.090 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2011 | 240 | 0.080 |
Why?
|
| Task Performance and Analysis | 1 | 2010 | 150 | 0.080 |
Why?
|
| Child, Preschool | 2 | 2013 | 3187 | 0.080 |
Why?
|
| Prostatic Neoplasms | 1 | 2014 | 778 | 0.080 |
Why?
|
| Activities of Daily Living | 1 | 2010 | 319 | 0.080 |
Why?
|
| beta-Lactamases | 2 | 2018 | 33 | 0.080 |
Why?
|
| Focus Groups | 2 | 2014 | 247 | 0.080 |
Why?
|
| Costs and Cost Analysis | 1 | 2008 | 193 | 0.070 |
Why?
|
| Crystallography, X-Ray | 1 | 2007 | 190 | 0.070 |
Why?
|
| Occupational Therapy | 1 | 2008 | 80 | 0.070 |
Why?
|
| Education, Medical, Continuing | 1 | 2008 | 136 | 0.070 |
Why?
|
| Adolescent | 3 | 2016 | 8912 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2016 | 7029 | 0.070 |
Why?
|
| Catheters, Indwelling | 1 | 2006 | 72 | 0.070 |
Why?
|
| Adult | 6 | 2017 | 21403 | 0.060 |
Why?
|
| Geriatrics | 1 | 2006 | 69 | 0.060 |
Why?
|
| Gram-Negative Bacterial Infections | 2 | 2019 | 62 | 0.060 |
Why?
|
| Models, Molecular | 1 | 2007 | 546 | 0.060 |
Why?
|
| Child | 2 | 2013 | 6405 | 0.060 |
Why?
|
| Nurse-Patient Relations | 1 | 2003 | 34 | 0.060 |
Why?
|
| Nursing Care | 1 | 2003 | 18 | 0.060 |
Why?
|
| Arm | 1 | 2004 | 59 | 0.060 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2003 | 61 | 0.060 |
Why?
|
| Hand | 1 | 2004 | 90 | 0.060 |
Why?
|
| North America | 1 | 2003 | 112 | 0.050 |
Why?
|
| United Kingdom | 1 | 2003 | 152 | 0.050 |
Why?
|
| Morale | 1 | 2002 | 1 | 0.050 |
Why?
|
| Benchmarking | 1 | 2003 | 91 | 0.050 |
Why?
|
| Role | 1 | 2002 | 25 | 0.050 |
Why?
|
| Australia | 1 | 2003 | 235 | 0.050 |
Why?
|
| Patient Care | 1 | 2002 | 61 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 1536 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2016 | 1745 | 0.050 |
Why?
|
| Young Adult | 1 | 2013 | 5717 | 0.050 |
Why?
|
| Time Factors | 1 | 2010 | 4655 | 0.050 |
Why?
|
| Cardiac Catheterization | 1 | 2003 | 419 | 0.050 |
Why?
|
| Patient Satisfaction | 1 | 2003 | 378 | 0.050 |
Why?
|
| Drug Repositioning | 1 | 2019 | 8 | 0.040 |
Why?
|
| Aging | 1 | 2006 | 911 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2010 | 111 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2017 | 3705 | 0.040 |
Why?
|
| beta-Lactamase Inhibitors | 1 | 2018 | 9 | 0.040 |
Why?
|
| Ligands | 1 | 2019 | 317 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2002 | 447 | 0.040 |
Why?
|
| Carbapenems | 1 | 2018 | 7 | 0.040 |
Why?
|
| Methods | 1 | 2017 | 156 | 0.040 |
Why?
|
| Virtual Reality | 1 | 2017 | 13 | 0.040 |
Why?
|
| Alkylation | 1 | 2016 | 26 | 0.040 |
Why?
|
| Carboxylic Acids | 1 | 2016 | 24 | 0.040 |
Why?
|
| Fluorine Radioisotopes | 1 | 2016 | 13 | 0.030 |
Why?
|
| Vero Cells | 1 | 2016 | 13 | 0.030 |
Why?
|
| Perception | 1 | 2017 | 189 | 0.030 |
Why?
|
| Problem-Based Learning | 1 | 2016 | 72 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 2017 | 765 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2011 | 1851 | 0.030 |
Why?
|
| Bacterial Proteins | 1 | 2017 | 245 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2016 | 199 | 0.030 |
Why?
|
| Protein Binding | 1 | 2018 | 1027 | 0.030 |
Why?
|
| Bacteria | 1 | 2016 | 193 | 0.030 |
Why?
|
| Middle Aged | 4 | 2017 | 21147 | 0.030 |
Why?
|
| Self Report | 1 | 2016 | 371 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 2016 | 221 | 0.030 |
Why?
|
| Exercise Therapy | 1 | 2016 | 183 | 0.030 |
Why?
|
| Medical Staff | 1 | 2014 | 5 | 0.030 |
Why?
|
| Men's Health | 1 | 2014 | 8 | 0.030 |
Why?
|
| Nursing Staff | 1 | 2014 | 30 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 201 | 0.030 |
Why?
|
| Urinary Incontinence | 1 | 2014 | 67 | 0.030 |
Why?
|
| Outpatients | 1 | 2014 | 127 | 0.030 |
Why?
|
| Fatigue | 1 | 2014 | 132 | 0.030 |
Why?
|
| Internal Medicine | 1 | 2014 | 118 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2016 | 706 | 0.030 |
Why?
|
| Chemistry Techniques, Synthetic | 1 | 2012 | 7 | 0.030 |
Why?
|
| Pain Management | 1 | 2014 | 186 | 0.030 |
Why?
|
| Pain | 1 | 2016 | 472 | 0.030 |
Why?
|
| Cyclohexenes | 1 | 2011 | 2 | 0.030 |
Why?
|
| Complex Mixtures | 1 | 2011 | 14 | 0.030 |
Why?
|
| Hydroxylamines | 1 | 2011 | 20 | 0.030 |
Why?
|
| Biological Transport | 1 | 2012 | 210 | 0.030 |
Why?
|
| Anthropology, Cultural | 1 | 2011 | 4 | 0.020 |
Why?
|
| Seeds | 1 | 2011 | 23 | 0.020 |
Why?
|
| Acrylic Resins | 1 | 2011 | 48 | 0.020 |
Why?
|
| Pseudomonas Infections | 1 | 2012 | 83 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2013 | 567 | 0.020 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2012 | 133 | 0.020 |
Why?
|
| Social Support | 1 | 2014 | 423 | 0.020 |
Why?
|
| Muscle Strength | 1 | 2011 | 62 | 0.020 |
Why?
|
| Goals | 1 | 2011 | 65 | 0.020 |
Why?
|
| Parent-Child Relations | 1 | 2011 | 98 | 0.020 |
Why?
|
| Esters | 1 | 2011 | 22 | 0.020 |
Why?
|
| Aged | 3 | 2016 | 14862 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 2279 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2011 | 381 | 0.020 |
Why?
|
| Postural Balance | 1 | 2011 | 93 | 0.020 |
Why?
|
| G2 Phase | 1 | 2010 | 26 | 0.020 |
Why?
|
| Amides | 1 | 2011 | 86 | 0.020 |
Why?
|
| Metals | 1 | 2011 | 100 | 0.020 |
Why?
|
| Tubulin | 1 | 2010 | 60 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2016 | 2358 | 0.020 |
Why?
|
| Microtubules | 1 | 2010 | 104 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 3259 | 0.020 |
Why?
|
| Geriatric Assessment | 1 | 2010 | 107 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2009 | 169 | 0.020 |
Why?
|
| Cell Division | 1 | 2010 | 541 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2010 | 4848 | 0.020 |
Why?
|
| Walking | 1 | 2010 | 241 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2011 | 1174 | 0.020 |
Why?
|
| Motor Activity | 1 | 2010 | 621 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2010 | 506 | 0.020 |
Why?
|
| Animals | 1 | 2016 | 20881 | 0.010 |
Why?
|
| United States | 1 | 2006 | 7367 | 0.010 |
Why?
|